Company profile: Kiyatec
1.1 - Company Overview
Company description
- Provider of ex vivo 3D cell culture technology that uses a patient's own living tumor cells to create functional microtumor models for testing cancer therapies and predicting response. Offers 3D Predict Glioma and 3D Predict Oncology, patient-specific microtumor creation (up to 1,000) for drug testing, and a HIPAA-compliant portal delivering patient-specific reports within 7-10 days to aid treatment decisions.
Products and services
- 3D Predict Oncology: A patient-derived test that uses functional 3D tumor models to predict therapeutic responses across various cancer types, aiding treatment decisions by testing a battery of cancer therapies
- 3D Predict Glioma: A glioma-specific test leveraging patient-derived glioma cells in functional 3D culture to predict responses to various cancer therapies, aiding treatment decisions
- Ex vivo 3D cell culture technology: A patient-specific platform that grows the patient’s own living cancer cells into 3D models to test responses to different chemotherapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kiyatec
Artiva Bio
HQ: United States
Website
- Description: Provider of allogeneic NK cell therapies and an umbilical cord blood–based manufacturing platform for off-the-shelf use. Products include AlloNK, a non-genetically modified NK therapy enhancing monoclonal antibody or NK engager activity in trials for autoimmune diseases and cancers; AB-201, a clinical-stage HER2-targeted CAR-NK for solid tumors; and AB-205, a preclinical CAR-NK for CD5+ T-cell lymphomas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artiva Bio company profile →
Gilupi
HQ: Germany
Website
- Description: Provider of medical devices and diagnostic solutions for in vivo isolation and analysis of rare circulating cells from blood. Offers GILUPI CellCollector for enriching circulating tumor cells, liquid biopsy sampling, immunofluorescence microscopy, NuPLex technology for RNA detection, and next-generation sequencing for genetic analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gilupi company profile →
SamanTree Medical
HQ: Switzerland
Website
- Description: Provider of confocal microscopy-based intraoperative imaging solutions for cancer surgery, enabling accurate full margin control and immediate visualization of excised human tissue specimens. Offers the Histolog Scanner, Histolog Dip stain, Histolog Dish protection, Histolog Viewer software, and Histolog Digital Solution for image management, storage, sharing, and remote collaboration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SamanTree Medical company profile →
Xspray Pharma
HQ: Sweden
Website
- Description: Provider of improved and generic versions of marketed protein kinase inhibitors, using patented Hynap Technology to create amorphous formulations for faster post-patent entry. Portfolio includes Dasynoc (improved dasatinib for CML/ALL with lower dose, reduced absorption variability, and gastric acid suppressant compatibility), XS004 (dasatinib), and XS025 (cabozantinib for renal cell carcinoma and other cancers).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xspray Pharma company profile →
MOMA Therapeutics
HQ: United States
Website
- Description: Provider of precision-medicine drug discovery targeting molecular machines involved in disease, enabled by a biomechanics engine integrating biochemistry, biophysics, structural biology, computation, chemistry, and functional genomics. Advancing precision oncology programs toward clinical trials and collaborating with Roche on a five-year effort to identify critical cancer dependencies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MOMA Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kiyatec
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kiyatec
2.2 - Growth funds investing in similar companies to Kiyatec
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kiyatec
4.2 - Public trading comparable groups for Kiyatec
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →